Seattle Genetics, Takeda's Cancer Drug Meets Main Goal In Trial

September 29, 2014 12:55 PM

2 0

Seattle Genetics, Takeda's Cancer Drug Meets Main Goal In Trial

(Reuters) - Seattle Genetics Inc and Takeda Pharmaceutical Co Ltd said their approved cancer drug was successfully used as a consolidation therapy in a late-stage trial for patients with a type of lymphatic cancer.

Consolidation therapy is given to cancer patients who have undergone initial therapy and kills any cancer cells that may be left in the body.

Read more

To category page

Loading...